GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: May 29, 2003, 15:08:32 ; Search time 70 Seconds
(without alignments)
154.190 Million cell updates/sec

Title: US-09-924-102-2
Perfect score: 418
Sequence: 1 MLLSTHLFIYLFIYFLSYSL.....RWGGQGGRGGTADTGGMFLS 81

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_101002:*
1: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:*
2: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:*
3: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1982.DAT:*
4: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:*
5: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:*
6: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:*
7: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:*
8: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:*
9: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1988.DAT:*
10: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:*
11: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:*
12: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:*
13: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:*
14: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:*
15: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:*
16: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1995.DAT:*
17: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:*
18: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:*
19: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1998.DAT:*
20: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1999.DAT:*
21: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2000.DAT:*
22: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2001.DAT:*
23: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	418	100.0	81	23	AAE19840	Human homologue of
2	90	21.5	20	23	AAE19842	Human hRpr derived
3	81	19.4	77	21	AAG02365	Human secreted pro
4	78.5	18.8	61	22	AAM88846	Human immune/haema
5	78.5	18.8	115	22	ABG10494	Novel human diagno
6	78	18.7	281	22	AAU87124	Novel central nerv
7	77	18.4	77	22	AAO06132	Human polypeptide
8	77	18.4	120	20	AAY74184	Human prostate tum
9	75	17.9	79	22	AAO13129	Human polypeptide
10	75	17.9	182	22	ABG26501	Novel human diagno
11	74.5	17.8	61	22	AAM91214	Human immune/haema
12	74.5	17.8	99	22	AAO07806	Human polypeptide
13	73.5	17.6	924	22	ABG29845	Novel human diagno
14	73	17.5	59	22	AAM86657	Human immune/haema
15	73	17.5	482	22	AAG84911	Shrimp white spot
16	72	17.2	102	22	AAM25887	Human protein sequ
17	71	17.0	163	22	AAG75462	Human colon cancer
18	71	17.0	181	22	AAU29487	Human G protein-co
19	71	17.0	181	23	ABG60775	Novel G protein co
20	70.5	16.9	39	22	AAM85158	Human immune/haema
21	70.5	16.9	87	22	ABG19765	Novel human diagno
22	70.5	16.9	1049	22	ABB60701	Drosophila melanog
23	69	16.5	655	22	ABB61625	Drosophila melanog
24	68.5	16.4	156	22	AAU31343	Novel human secret
25	68	16.3	72	22	AAO07607	Human polypeptide
26	68	16.3	462	22	AAU35372	Haemophilus influe
27	67.5	16.1	100	23	ABB04598	Human centrosomal
28	67.5	16.1	734	22	ABG18054	Novel human diagno
29	67	16.0	808	22	ABB70322	Drosophila melanog
30	66.5	15.9	115	22	AAO04729	Human polypeptide
31	66.5	15.9	135	22	AAO04856	Human polypeptide
32	66	15.8	55	22	AAM83720	Human immune/haema
33	66	15.8	118	20	AAY59777	Human normal ovari
34	65.5	15.7	1783	22	ABB63930	Drosophila melanog
35	65	15.6	65	15	AAR55789	Cell death reaper
36	65	15.6	65	22	ABB60552	Drosophila melanog
37	65	15.6	65	22	AAG65246	D melanogaster apo
38	65	15.6	65	23	AAE19839	Drosophila melanog
39	65	15.6	138	21	AAB43352	Human ORFX ORF3116
40	65	15.6	138	23	ABP08478	Human ORFX protein
41	65	15.6	222	22	AAU69783	Human prostate cDN
42	65	15.6	222	22	AAM01138	Human prostate-spe
43	65	15.6	222	22	AAG99023	Human prostate-spe
44	65	15.6	222	23	ABB95243	Human P775P splice
45	65	15.6	287	22	ABG15575	Novel human diagno

ALIGNMENTS

RESULT 1
AAE19840
ID AAE19840 standard; Protein; 81 AA.
XX
AC AAE19840;
XX
DT 18-JUN-2002 (first entry)
XX
DE Human homologue of Drosophila melanogaster reaper protein (hRpr).
XX
KW Human; reaper protein; Rpr; detection; purification; screening;
KW therapy; tumour; cytostatic; protein.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Region 5..17
FT /label= Alpha_helix
FT Region 23..42
FT /label= Alpha_helix
FT Misc-difference 38
FT /note= "Encoded by AAA"
FT Region 43..55
FT /label= Alpha_helix
XX
PN WO200212540-A2.
XX
PD 14-FEB-2002.
XX
PF 08-AUG-2001; 2001WO-US24765.
XX
PR 08-AUG-2000; 2000US-223699P.
XX

PA (UYDU-) UNIV DUKE.
XX
PI Kornbluth SA, Holley C;
XX
DR WPI; 2002-241769/29.
DR N-PSDB; AAD31598.
XX
PT New human homologue of Drosophila melanogaster reaper protein (hRpr),
PT useful for generating antibodies and for screening compounds, which can
PT inhibit or enhance hRpr activity -
XX
PS Claim 1; Fig 1; 45pp; English.
XX
CC The invention relates to human homologue of Drosophila melanogaster
CC Reaper protein (hRpr) and its corresponding nucleic acid. The hRpr
CC polypeptides are useful for generating antibodies, which can be used
CC in detection or purification protocols designed to detect or purify
CC the polypeptide to which the antibody is directed. These sequences
CC are also used for screening compounds, which can enhance or inhibit
CC hRpr and for treating tumours. The hRpr polynucleotides are useful
CC as a probe or primer. The present sequence is human homologue of
CC Drosophila melanogaster reaper protein (hRpr).
XX
SQ Sequence 81 AA;

Query Match 100.0%; Score 418; DB 23; Length 81;
Best Local Similarity 100.0%; Pred. No. 9.1e-42;
Matches 81; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MLLSTHLFIYLFIYFLSYSLGDRARLCLRKTKQQQKEQQILRQSEVLFRSETLRKTGKKG 60
Db 1 MLLSTHLFIYLFIYFLSYSLGDRARLCLRKTKQQQKEQQILRQSEVLFRSETLRKTGKKG 60

Qy 61 RRWGGQGGRGGTADTGGMFLS 81
Db 61 RRWGGQGGRGGTADTGGMFLS 81

RESULT 2
AAE19842
ID AAE19842 standard; peptide; 20 AA.
XX
AC AAE19842;
XX
DT 18-JUN-2002 (first entry)
XX
DE Human hRpr derived peptide.
XX
KW Human; reaper protein; Rpr; detection; purification; screening;
KW therapy; tumour; cytostatic.
XX
OS Homo sapiens.
XX
PN WO200212540-A2.
XX
PD 14-FEB-2002.
XX
PF 08-AUG-2001; 2001WO-US24765.
XX
PR 08-AUG-2000; 2000US-223699P.
XX
PA (UYDU-) UNIV DUKE.
XX
PI Kornbluth SA, Holley C;
XX
DR WPI; 2002-241769/29.
XX
PT New human homologue of Drosophila melanogaster reaper protein (hRpr),
PT useful for generating antibodies and for screening compounds, which can
PT inhibit or enhance hRpr activity -
XX
PS Example 1; Page 19; 45pp; English.
XX
CC The invention relates to human homologue of Drosophila melanogaster
CC Reaper protein (hRpr) and its corresponding nucleic acid. The hRpr
CC polypeptides are useful for generating antibodies, which can be used
CC in detection or purification protocols designed to detect or purify
CC the polypeptide to which the antibody is directed. These sequences
CC are also used for screening compounds, which can enhance or inhibit
CC hRpr and for treating tumours. The hRpr polynucleotides are useful
CC as a probe or primer. The present sequence is human homologue of
CC Drosophila melanogaster reaper protein (hRpr) derived peptide.
XX
SQ Sequence 20 AA;

Query Match 21.5%; Score 90; DB 23; Length 20;
Best Local Similarity 95.0%; Pred. No. 0.00092;
Matches 19; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 36 KEQQILRQSEVLFRSETLRK 55
Db 1 KEKQILRQSEVLFRSETLRK 20

RESULT 3
AAG02365
ID AAG02365 standard; Protein; 77 AA.
XX
AC AAG02365;
XX
DT 06-OCT-2000 (first entry)
XX
DE Human secreted protein, SEQ ID NO: 6446.
XX
KW Human; 5' EST; expressed sequence tag; secreted protein; cDNA isolation;
KW gene therapy; chromosome mapping.
XX
OS Homo sapiens.
XX
PN EP1033401-A2.
XX
PD 06-SEP-2000.
XX
PF 21-FEB-2000; 2000EP-0200610.
XX
PR 26-FEB-1999; 99US-0122487.
XX
PA (GEST) GENSET.
XX
PI Dumas Milne Edwards J, Duclert A, Giordano J;
XX
DR WPI; 2000-500381/45.
DR N-PSDB; AAC02371.
XX
PT New nucleic acid that is a 5' expressed sequence tag (5' EST) for
PT obtaining cDNAs and genomic DNAs that correspond to 5'ESTs and for
PT diagnostic, forensic, gene therapy and chromosome mapping procedures -
XX
PS Claim 13; SEQ ID 6446; 71pp + CD-ROM; English.
XX
CC The present sequence is a polypeptide encoded by one of a large number
CC of 5' ESTs derived from mRNAs encoding secreted proteins. The 5' ESTs
CC were prepared from total human RNAs or polyA+ RNAs derived from 30
CC different tissues. EST sequences usually correspond mainly to the 3'
CC untranslated region (UTR) of the mRNA because they are often obtained
CC from oligo-dT primed cDNA libraries. Such ESTs are not well suited for
CC isolating cDNA sequences derived from the 5' ends of mRNAs and even in
CC those cases where longer cDNA sequences have been obtained, the full 5'
CC UTR is rarely included. 5' ESTs are derived from mRNAs with intact 5'
CC ends and can therefore be used to obtain full length cDNAs and genomic
CC DNAs. 5' ESTs are also used in diagnostic, forensic, gene therapy and
CC chromosome mapping procedures. They are used to obtain upstream
CC regulatory sequences and to design expression and secretion vectors.
XX
SQ Sequence 77 AA;

```
  Query Match           19.4%;  Score 81;  DB 21;  Length 77;
  Best Local Similarity  41.7%;  Pred. No. 0.046;
  Matches   20;  Conservative   10;  Mismatches   12;  Indels    6;  Gaps    2;

Qy          7 LFIYLFIYFLSY--SLGDRARLCLRKTKQQQKEQQILRQSEVLFRSET 52
              ||: ||:: : :   ||:||||||::| :| |   |    :|  || |
Db         31 LFVCLFVFEMEFHSGLGNRARLCLKQTNKQTKGLYI----QVKIRSVT 74


RESULT 4
AAM88846
ID   AAM88846 standard; Protein; 61 AA.
XX
AC   AAM88846;
XX
DT   07-NOV-2001  (first entry)
XX
DE   Human immune/haematopoietic antigen SEQ ID NO:16439.
XX
KW   Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW   cytostatic; gene therapy; vaccine; metastasis.
XX
OS   Homo sapiens.
XX
PN   WO200157182-A2.
XX
PD   09-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US01354.
XX
PR   31-JAN-2000; 2000US-0179065.
PR   04-FEB-2000; 2000US-0180628.
PR   24-FEB-2000; 2000US-0184664.
PR   02-MAR-2000; 2000US-0186350.
PR   16-MAR-2000; 2000US-0189874.
PR   17-MAR-2000; 2000US-0190076.
PR   18-APR-2000; 2000US-0198123.
PR   19-MAY-2000; 2000US-0205515.
PR   07-JUN-2000; 2000US-0209467.
PR   28-JUN-2000; 2000US-0214886.
PR   30-JUN-2000; 2000US-0215135.
PR   07-JUL-2000; 2000US-0216647.
PR   07-JUL-2000; 2000US-0216880.
PR   11-JUL-2000; 2000US-0217487.
PR   11-JUL-2000; 2000US-0217496.
PR   14-JUL-2000; 2000US-0218290.
PR   26-JUL-2000; 2000US-0220963.
PR   26-JUL-2000; 2000US-0220964.
PR   14-AUG-2000; 2000US-0224518.
PR   14-AUG-2000; 2000US-0224519.
PR   14-AUG-2000; 2000US-0225213.
PR   14-AUG-2000; 2000US-0225214.
PR   14-AUG-2000; 2000US-0225266.
PR   14-AUG-2000; 2000US-0225267.
PR   14-AUG-2000; 2000US-0225268.
PR   14-AUG-2000; 2000US-0225270.
PR   14-AUG-2000; 2000US-0225447.
PR   14-AUG-2000; 2000US-0225757.
PR   14-AUG-2000; 2000US-0225758.
PR   14-AUG-2000; 2000US-0225759.
PR   18-AUG-2000; 2000US-0226279.
PR   22-AUG-2000; 2000US-0226681.
PR   22-AUG-2000; 2000US-0226868.
PR   22-AUG-2000; 2000US-0227182.
PR   23-AUG-2000; 2000US-0227009.
PR   30-AUG-2000; 2000US-0228924.
PR   01-SEP-2000; 2000US-0229287.
PR   01-SEP-2000; 2000US-0229343.
PR   01-SEP-2000; 2000US-0229344.
PR   01-SEP-2000; 2000US-0229345.
PR   05-SEP-2000; 2000US-0229509.
PR   05-SEP-2000; 2000US-0229513.
PR   06-SEP-2000; 2000US-0230437.
PR   06-SEP-2000; 2000US-0230438.
PR   08-SEP-2000; 2000US-0231242.
PR   08-SEP-2000; 2000US-0231243.
PR   08-SEP-2000; 2000US-0231244.
PR   08-SEP-2000; 2000US-0231413.
PR   08-SEP-2000; 2000US-0231414.
PR   08-SEP-2000; 2000US-0232080.
PR   08-SEP-2000; 2000US-0232081.
PR   12-SEP-2000; 2000US-0231968.
PR   14-SEP-2000; 2000US-0232397.
PR   14-SEP-2000; 2000US-0232398.
PR   14-SEP-2000; 2000US-0232399.
PR   14-SEP-2000; 2000US-0232400.
PR   14-SEP-2000; 2000US-0232401.
PR   14-SEP-2000; 2000US-0233063.
PR   14-SEP-2000; 2000US-0233064.
PR   14-SEP-2000; 2000US-0233065.
PR   21-SEP-2000; 2000US-0234223.
PR   21-SEP-2000; 2000US-0234274.
PR   25-SEP-2000; 2000US-0234997.
PR   25-SEP-2000; 2000US-0234998.
PR   26-SEP-2000; 2000US-0235484.
PR   27-SEP-2000; 2000US-0235834.
PR   27-SEP-2000; 2000US-0235836.
PR   29-SEP-2000; 2000US-0236327.
PR   29-SEP-2000; 2000US-0236367.
PR   29-SEP-2000; 2000US-0236368.
PR   29-SEP-2000; 2000US-0236369.
PR   29-SEP-2000; 2000US-0236370.
PR   02-OCT-2000; 2000US-0236802.
PR   02-OCT-2000; 2000US-0237037.
PR   02-OCT-2000; 2000US-0237038.
PR   02-OCT-2000; 2000US-0237039.
PR   02-OCT-2000; 2000US-0237040.
PR   13-OCT-2000; 2000US-0239935.
PR   13-OCT-2000; 2000US-0239937.
PR   20-OCT-2000; 2000US-0240960.
PR   20-OCT-2000; 2000US-0241221.
PR   20-OCT-2000; 2000US-0241785.
PR   20-OCT-2000; 2000US-0241786.
PR   20-OCT-2000; 2000US-0241787.
PR   20-OCT-2000; 2000US-0241808.
PR   20-OCT-2000; 2000US-0241809.
PR   20-OCT-2000; 2000US-0241826.
PR   01-NOV-2000; 2000US-0244617.
PR   08-NOV-2000; 2000US-0246474.
PR   08-NOV-2000; 2000US-0246475.
PR   08-NOV-2000; 2000US-0246476.
PR   08-NOV-2000; 2000US-0246477.
PR   08-NOV-2000; 2000US-0246478.
PR   08-NOV-2000; 2000US-0246523.
PR   08-NOV-2000; 2000US-0246524.
PR   08-NOV-2000; 2000US-0246525.
PR   08-NOV-2000; 2000US-0246526.
PR   08-NOV-2000; 2000US-0246527.
PR   08-NOV-2000; 2000US-0246528.
PR   08-NOV-2000; 2000US-0246532.
PR   08-NOV-2000; 2000US-0246609.
PR   08-NOV-2000; 2000US-0246610.
PR   08-NOV-2000; 2000US-0246611.
PR   08-NOV-2000; 2000US-0246613.
PR   17-NOV-2000; 2000US-0249207.
PR   17-NOV-2000; 2000US-0249208.
PR   17-NOV-2000; 2000US-0249209.
PR   17-NOV-2000; 2000US-0249210.
PR   17-NOV-2000; 2000US-0249211.
PR   17-NOV-2000; 2000US-0249212.
PR   17-NOV-2000; 2000US-0249213.
PR   17-NOV-2000; 2000US-0249214.
PR   17-NOV-2000; 2000US-0249215.
PR   17-NOV-2000; 2000US-0249216.
PR   17-NOV-2000; 2000US-0249217.
PR   17-NOV-2000; 2000US-0249218.
```

```
PR   17-NOV-2000; 2000US-0249244.
PR   17-NOV-2000; 2000US-0249245.
PR   17-NOV-2000; 2000US-0249264.
PR   17-NOV-2000; 2000US-0249265.
PR   17-NOV-2000; 2000US-0249297.
PR   17-NOV-2000; 2000US-0249299.
PR   17-NOV-2000; 2000US-0249300.
PR   01-DEC-2000; 2000US-0250160.
PR   01-DEC-2000; 2000US-0250391.
PR   05-DEC-2000; 2000US-0251030.
PR   05-DEC-2000; 2000US-0251988.
PR   05-DEC-2000; 2000US-0256719.
PR   06-DEC-2000; 2000US-0251479.
PR   08-DEC-2000; 2000US-0251856.
PR   08-DEC-2000; 2000US-0251868.
PR   08-DEC-2000; 2000US-0251869.
PR   08-DEC-2000; 2000US-0251989.
PR   08-DEC-2000; 2000US-0251990.
PR   11-DEC-2000; 2000US-0254097.
PR   05-JAN-2001; 2001US-0259678.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Barash SC,  Ruben SM;
XX
DR   WPI; 2001-483426/52.
DR   N-PSDB; AAK61627.
XX
PT   Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
PT   useful for preventing, diagnosing and/or treating cancers and
PT   metastasis -
XX
PS   Claim 11; SEQ ID NO 16439; 3071pp + Sequence Listing; English.
XX
CC   AAK54951 to AAK64702 encode the human immune/haematopoietic antigen (I)
CC   amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic
CC   activity, and can be used in gene therapy and vaccine production. (I)
CC   proteins and polynucleotides may be used in the prevention, diagnosis and
CC   treatment of diseases associated with inappropriate (I) expression. For
CC   example, they may be used to treat disorders associated with decreased
CC   expression by rectifying mutations or deletions in a patient's genome
CC   that affect the activity of (I) by expressing inactive proteins or to
CC   supplement the patients own production of (I). Additionally, (I)
CC   polynucleotides may be used to produce the secreted (I), by inserting
CC   the nucleic acids into a host cell and culturing the cell to express the
CC   protein. (I) proteins and polynucleotides may be used to prevent,
CC   diagnose and treat immune/haematopoietic-related diseases, especially
CC   cancers and cancer metastases of haematopoietic-derived cells. AAK64703
CC   to AAK87694 represent human immune/haematopoietic antigen genomic
CC   sequences from the present invention. AAK54942 to AAK54950 and AAM82169
CC   represent sequences used in the exemplification of the present invention.
XX
SQ   Sequence   61 AA;

  Query Match             18.8%;  Score 78.5;  DB 22;  Length 61;
  Best Local Similarity   43.9%;  Pred. No. 0.07;
  Matches   18;  Conservative    7;  Mismatches   11;  Indels    5;  Gaps    1;

Qy          2 LLSTHLFIYLFIYFL-----SYSLGDRARLCLRKTKQQQKE 37
              ||   |||:||||       : :   ||||||:| |:: :|
Db         14 LLRFSLFIHLFIYLFCDGVCTLAWATRARLCLKKKKERDRE 54


RESULT 5
ABG10494
ID   ABG10494 standard; Protein; 115 AA.
XX
AC   ABG10494;
XX
DT   13-FEB-2002  (first entry)
XX
DE   Novel human diagnostic protein #10485.
XX
KW   Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW   food supplement; medical imaging; diagnostic; genetic disorder.
XX
OS   Homo sapiens.
XX
PN   WO200175067-A2.
XX
PD   11-OCT-2001.
XX
PF   30-MAR-2001; 2001WO-US08631.
XX
PR   31-MAR-2000; 2000US-0540217.
PR   23-AUG-2000; 2000US-0649167.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Drmanac RT,  Liu C,  Tang YT;
XX
DR   WPI; 2001-639362/73.
DR   N-PSDB; AAS74681.
XX
PT   New isolated polynucleotide and encoded polypeptides, useful in
PT   diagnostics, forensics, gene mapping, identification of mutations
PT   responsible for genetic disorders or other traits and to assess
PT   biodiversity -
XX
PS   Claim 20; SEQ ID No 40853; 103pp; English.
XX
CC   The invention relates to isolated polynucleotide (I) and
CC   polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC   polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC   and gene mapping, and in recombinant production of (II). The
CC   polynucleotides are also used in diagnostics as expressed sequence tags
CC   for identifying expressed genes. (I) is useful in gene therapy techniques
CC   to restore normal activity of (II) or to treat disease states involving
CC   (II). (II) is useful for generating antibodies against it, detecting or
CC   quantitating a polypeptide in tissue, as molecular weight markers and as
CC   a food supplement. (II) and its binding partners are useful in medical
CC   imaging of sites expressing (II). (I) and (II) are useful for treating
CC   disorders involving aberrant protein expression or biological activity.
CC   The polypeptide and polynucleotide sequences have applications in
CC   diagnostics, forensics, gene mapping, identification of mutations
CC   responsible for genetic disorders or other traits to assess biodiversity
CC   and to produce other types of data and products dependent on DNA and
CC   amino acid sequences. ABG00010-ABG30377 represent novel human
CC   diagnostic amino acid sequences of the invention.
CC   Note: The sequence data for this patent did not appear in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   115 AA;

  Query Match             18.8%;  Score 78.5;  DB 22;  Length 115;
  Best Local Similarity   57.1%;  Pred. No. 0.14;
  Matches   16;  Conservative    7;  Mismatches    2;  Indels    3;  Gaps    1;

Qy         20 LGDRARLCLRKTKQQQKEQQILRQSEVL 47
              |||||||||:: :|||::||   | ::|
Db         65 LGDRARLCLKQQQQQQQQQQ---QQQLL 89


RESULT 6
AAU87124
ID   AAU87124 standard; Protein; 281 AA.
XX
AC   AAU87124;
XX
DT   05-JUN-2002  (first entry)
XX
DE   Novel central nervous system protein #34.
XX
KW   Central nervous system; CNS; autoimmune disease; rheumatoid arthritis;
KW   hyperproliferative disorder; neoplasm; cardiovascular disorder;
```

KW cardiac arrest; cerebrovascular disorder; ischaemia; angiogenesis;
KW nervous system disorder; Alzheimer's disease; AIDS; ocular disorder;
KW acquired immunodeficiency virus; dysphagia; gastrointestinal disorder;
KW adenocarcinoma; reproductive system disorder; testicular feminisation;
KW endocrine disorder; diabetes; cancer; leukaemia; neovascularisation;
KW respiratory disorder; renal disorder; kidney failure; blood disorder;
KW myocardial infarction; wound healing; cell proliferation; skin aging;
KW food additive; food preservative; gene therapy.
XX
OS Homo sapiens.
XX
PN WO200155318-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01332.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.

```
PR   08-DEC-2000; 2000US-0251856.
PR   08-DEC-2000; 2000US-0251868.
PR   08-DEC-2000; 2000US-0251869.
PR   08-DEC-2000; 2000US-0251989.
PR   08-DEC-2000; 2000US-0251990.
PR   11-DEC-2000; 2000US-0254097.
PR   05-JAN-2001; 2001US-0259678.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Barash SC,  Ruben SM;
XX
DR   WPI; 2001-581633/65.
DR   N-PSDB; ABK43454.
XX
PT   New isolated nucleic acid encoding a protein for diagnosing,
PT   preventing, treating or ameliorating medical conditions and used as
PT   food additives or preservatives -
XX
PS   Claim 9; SEQ ID No 642; 837pp; English.
XX
CC   The invention describes an isolated nucleic acid molecule (I) encoding a
CC   novel central nervous system protein. (I) and polypeptides (III) encoded
CC   by (I), are used to treat a medical conditions and in diagnosis of a
CC   pathological condition. Disorders which are diagnosed or treated include
CC   autoimmune diseases e.g. rheumatoid arthritis, hyperproliferative
CC   disorders e.g. neoplasms of the breast or liver, cardiovascular disorders
CC   e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral ischaemia,
CC   angiogenesis, nervous system disorders e.g. Alzheimer's disease and
CC   amylotrophic lateral sclerosis, infections caused by bacteria, viruses
CC   e.g. Acquired immunodeficiency virus (AIDS) and fungi, ocular disorders
CC   e.g. corneal infection, gastrointestinal disorders e.g. dysphagia,
CC   adenocarcinomas and irritable bowel syndrome, reproductive system
CC   disorders e.g. testicular feminisation, endocrine disorders e.g. diabetes
CC   and pituitary dwarfism, cancers and disorders at the cellular level e.g.
CC   leukaemia, disorders involving neovascularisation e.g. malignancies,
CC   respiratory disorders e.g. nonallergic rhinitis, renal disorders e.g.
CC   acute kidney failure and blood related disorders e.g. myocardial
CC   infarction. The polypeptides can also be used to aid wound healing and
CC   epithelial cell proliferation, to prevent skin aging due to sunburn, to
CC   maintain organs before transplantation, for supporting cell culture of
CC   primary tissues, to regenerate tissues and in chemotaxis. The
CC   polypeptides can also be used as a food additive or preservative to
CC   increase or decrease storage capabilities, fat content, lipid, protein,

  Query Match             18.7%;  Score 78;  DB 22;  Length 281;
  Best Local Similarity   36.4%;  Pred. No. 0.43;
  Matches   16;  Conservative   13;  Mismatches   15;  Indels    0;  Gaps    0;

Qy         19 SLGDRARLCLRKTKQQQKEQQILRQSEVLFRSETLRKTGKKGRR 62
              ||||||| ||:| | ::|:|:  :: :   : :  :|  || ::
Db        228 SLGDRARRCLKKKKNKKKKQKKKKKKKKKKKKKKKKKKKKKKKK 271


RESULT 7
AAO06132
ID   AAO06132 standard; Protein; 77 AA.
XX
AC   AAO06132;
XX
DT   06-NOV-2001  (first entry)
XX
DE   Human polypeptide SEQ ID NO 20024.
XX
KW   Human; cytokine; cell proliferation; cell differentiation; gene therapy;
KW   vaccine; peptide therapy; stem cell growth factor; haematopoiesis;
KW   tissue growth factor; immunomodulatory; cancer; leukaemia;
KW   nervous system disorders; arthritis; inflammation.
XX
OS   Homo sapiens.
XX
PN   WO200164835-A2.
XX
PD   07-SEP-2001.
XX
PF   26-FEB-2001; 2001WO-US04927.
XX
PR   28-FEB-2000; 2000US-0515126.
PR   18-MAY-2000; 2000US-0577409.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Tang YT,  Liu C,  Drmanac RT;
XX
DR   WPI; 2001-514838/56.
DR   N-PSDB; AAI86063.
XX
PT   Isolated nucleic acids and polypeptides, useful for preventing
PT   diagnosing and treating e.g. leukaemia, inflammation and immune
PT   disorders -
XX
PS   Claim 20; SEQ ID NO 20024; 1399pp + Sequence Listing; English.
XX
CC   The invention relates to human polynucleotides (AAI79941-AAI93841) and
CC   the encoded proteins (AAO00010-AAO13910) that exhibit activity elating to
CC   cytokine, cell proliferation or cell differentiation or which may induce
CC   production of other cytokines in other cell populations. The
CC   polynucleotides and polypeptides are useful in gene therapy, vaccines or
CC   peptide therapy. The polypeptides have various cytokine-like activities,
CC   e.g. stem cell growth factor activity, haematopoiesis regulating
CC   activity, tissue growth factor activity, immunomodulatory activity and
CC   activin/inhibin activity and may be useful in the diagnosis and/or
CC   treatment of cancer, leukaemia, nervous system disorders, arthritis and
CC   inflammation.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   77 AA;

  Query Match             18.4%;  Score 77;  DB 22;  Length 77;
  Best Local Similarity   38.0%;  Pred. No. 0.14;
  Matches   19;  Conservative   10;  Mismatches   13;  Indels    8;  Gaps    1;

Qy         16 LSYSLGDRARLCLRKTKQQQKEQQILRQSEVLFRSETLRKTGKKGRRWGG 65
              | ||||:||||||:| |:        :: :|    :  :|  || :: ||
Db         34 LHYSLGNRARLCLKKKKK--------KKFKVFPPQKKKKKKKKKKKKGG 75


RESULT 8
AAY74184
ID   AAY74184 standard; Protein; 120 AA.
XX
AC   AAY74184;
XX
DT   14-MAR-2000  (first entry)
XX
DE   Human prostate tumor EST fragment derived protein #371.
XX
KW   Pancreas; tumor; EST; expressed sequence tag; human; cytostatic;
KW   treatment.
XX
OS   Homo sapiens.
XX
PN   DE19820190-A1.
XX
PD   04-NOV-1999.
XX
PF   28-APR-1998;   98DE-1020190.
XX
PR   28-APR-1998;   98DE-1020190.
XX
PA   (META-) METAGEN GES GENOMFORSCHUNG MBH.
XX
PI   Rosenthal A,  Specht T,  Hinzmann B,  Schmitt A,  Pilarsky C,  Dahl E;
XX
```

```
DR   WPI; 1999-621386/54.
DR   N-PSDB; AAZ52980.
XX
PT   New human nucleic acid sequences from pancreatic tumors, and related
PT   proteins -
XX
PS   Claim 23; Page 464; 502pp; German.
XX
CC   This invention describes novel polypeptides and their encoding nucleic
CC   acids derived from human pancreatic tumor tissue which have cytostatic
CC   activity. The sequences are also useful in producing pharmaceutical
CC   compositions for treatment of pancreatic tumors. AAY73814-Y74252
CC   represent protein fragments encoded by the human pancreatic tumor cDNA
CC   library derived expressed sequence tag (EST) sequences represented in
CC   AAZ52858-Z53014.
XX
SQ   Sequence   120 AA;

  Query Match          18.4%;  Score 77;  DB 20;  Length 120;
  Best Local Similarity   30.8%;  Pred. No. 0.22;
  Matches   24;  Conservative    7;  Mismatches   23;  Indels   24;  Gaps    3;

Qy          5 THLFIYLFIYFLSYSLGDRARLCLRKTKQQQKEQQILRQSEVLFRSETLRKTGKKGRRWG 64
              |:|| : | :||  |||                  :|    |||||     |      |
Db          2 TYLFFFFFFFFLGRSLG-----------------FIRSVGTLFRSEAPPSHGV-----G 38

Qy         65 GQGGRGGTAD-TGGMFLS 81
                ||||  ::  ||  :|
Db         39 DSGGRGNPSEHPGGCVVS 56


RESULT 9
AAO13129
ID   AAO13129 standard; Protein; 79 AA.
XX
AC   AAO13129;
XX
DT   06-NOV-2001  (first entry)
XX
DE   Human polypeptide SEQ ID NO 27021.
XX
KW   Human; cytokine; cell proliferation; cell differentiation; gene therapy;
KW   vaccine; peptide therapy; stem cell growth factor; haematopoiesis;
KW   tissue growth factor; immunomodulatory; cancer; leukaemia;
KW   nervous system disorders; arthritis; inflammation.
XX
OS   Homo sapiens.
XX
PN   WO200164835-A2.
XX
PD   07-SEP-2001.
XX
PF   26-FEB-2001; 2001WO-US04927.
XX
PR   28-FEB-2000; 2000US-0515126.
PR   18-MAY-2000; 2000US-0577409.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Tang YT,  Liu C,  Drmanac RT;
XX
DR   WPI; 2001-514838/56.
DR   N-PSDB; AAI93060.
XX
PT   Isolated nucleic acids and polypeptides, useful for preventing
PT   diagnosing and treating e.g. leukaemia, inflammation and immune
PT   disorders -
XX
PS   Claim 20; SEQ ID NO 27021; 1399pp + Sequence Listing; English.
XX
CC   The invention relates to human polynucleotides (AAI79941-AAI93841) and
CC   the encoded proteins (AAO00010-AAO13910) that exhibit activity elating to
CC   cytokine, cell proliferation or cell differentiation or which may induce
CC   production of other cytokines in other cell populations. The
CC   polynucleotides and polypeptides are useful in gene therapy, vaccines or
CC   peptide therapy. The polypeptides have various cytokine-like activities,
CC   e.g. stem cell growth factor activity, haematopoiesis regulating
CC   activity, tissue growth factor activity, immunomodulatory activity and
CC   activin/inhibin activity and may be useful in the diagnosis and/or
CC   treatment of cancer, leukaemia, nervous system disorders, arthritis and
CC   inflammation.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   79 AA;

  Query Match          17.9%;  Score 75;  DB 22;  Length 79;
  Best Local Similarity   52.0%;  Pred. No. 0.24;
  Matches   13;  Conservative    8;  Mismatches    4;  Indels    0;  Gaps    0;

Qy         16 LSYSLGDRARLCLRKTKQQQKEQQI 40
              | :||| :|||||:| |::||:: :
Db         42 LDFSLGGKARLCLKKKKKKQKQKTL 66


RESULT 10
ABG26501
ID   ABG26501 standard; Protein; 182 AA.
XX
AC   ABG26501;
XX
DT   18-FEB-2002  (first entry)
XX
DE   Novel human diagnostic protein #26492.
XX
KW   Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW   food supplement; medical imaging; diagnostic; genetic disorder.
XX
OS   Homo sapiens.
XX
PN   WO200175067-A2.
XX
PD   11-OCT-2001.
XX
PF   30-MAR-2001; 2001WO-US08631.
XX
PR   31-MAR-2000; 2000US-0540217.
PR   23-AUG-2000; 2000US-0649167.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Drmanac RT,  Liu C,  Tang YT;
XX
DR   WPI; 2001-639362/73.
DR   N-PSDB; AAS90688.
XX
PT   New isolated polynucleotide and encoded polypeptides, useful in
PT   diagnostics, forensics, gene mapping, identification of mutations
PT   responsible for genetic disorders or other traits and to assess
PT   biodiversity -
XX
PS   Claim 20; SEQ ID No 56860; 103pp; English.
XX
CC   The invention relates to isolated polynucleotide (I) and
CC   polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC   polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC   and gene mapping, and in recombinant production of (II). The
CC   polynucleotides are also used in diagnostics as expressed sequence tags
CC   for identifying expressed genes. (I) is useful in gene therapy. techniques
CC   to restore normal activity of (II) or to treat disease states involving
CC   (II). (II) is useful for generating antibodies against it, detecting or
CC   quantitating a polypeptide in tissue, as molecular weight markers and as
CC   a food supplement. (II) and its binding partners are useful in medical
CC   imaging of sites expressing (II). (I) and (II) are useful for treating
CC   disorders involving aberrant protein expression or biological activity.
```

```
CC   The polypeptide and polynucleotide sequences have applications in
CC   diagnostics, forensics, gene mapping, identification of mutations
CC   responsible for genetic disorders or other traits to assess biodiversity
CC   and to produce other types of data and products dependent on DNA and
CC   amino acid sequences. ABG00010-ABG30377 represent novel human
CC   diagnostic amino acid sequences of the invention.
CC   Note: The sequence data for this patent did not appear in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   182 AA;

  Query Match             17.9%;  Score 75;  DB 22;  Length 182;
  Best Local Similarity   40.0%;  Pred. No. 0.6;
  Matches   20;  Conservative    7;  Mismatches   11;  Indels   12;  Gaps    2;

Qy         16 LSYSLGDRARLCL---RKTKQQQKEQQILRQSEVLFRSETLRKTGKKGRR 62
              | :||||| : ||   |: |:|||:|:         |    ||  || |:
Db          4 LPFSLGDRVKHCLQKKRRRKKQQKKQK---------RKRKKRKRRKKRRK 44


RESULT 11
AAM91214
ID   AAM91214 standard; Protein; 61 AA.
XX
AC   AAM91214;
XX
DT   07-NOV-2001  (first entry)
XX
DE   Human immune/haematopoietic antigen SEQ ID NO:18807.
XX
KW   Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW   cytostatic; gene therapy; vaccine; metastasis.
XX
OS   Homo sapiens.
XX
PN   WO200157182-A2.
XX
PD   09-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US01354.
XX
PR   31-JAN-2000; 2000US-0179065.
PR   04-FEB-2000; 2000US-0180628.
PR   24-FEB-2000; 2000US-0184664.
PR   02-MAR-2000; 2000US-0186350.
PR   16-MAR-2000; 2000US-0189874.
PR   17-MAR-2000; 2000US-0190076.
PR   18-APR-2000; 2000US-0198123.
PR   19-MAY-2000; 2000US-0205515.
PR   07-JUN-2000; 2000US-0209467.
PR   28-JUN-2000; 2000US-0214886.
PR   30-JUN-2000; 2000US-0215135.
PR   07-JUL-2000; 2000US-0216647.
PR   07-JUL-2000; 2000US-0216880.
PR   11-JUL-2000; 2000US-0217487.
PR   11-JUL-2000; 2000US-0217496.
PR   14-JUL-2000; 2000US-0218290.
PR   26-JUL-2000; 2000US-0220963.
PR   26-JUL-2000; 2000US-0220964.
PR   14-AUG-2000; 2000US-0224518.
PR   14-AUG-2000; 2000US-0224519.
PR   14-AUG-2000; 2000US-0225213.
PR   14-AUG-2000; 2000US-0225214.
PR   14-AUG-2000; 2000US-0225266.
PR   14-AUG-2000; 2000US-0225267.
PR   14-AUG-2000; 2000US-0225268.
PR   14-AUG-2000; 2000US-0225270.
PR   14-AUG-2000; 2000US-0225447.
PR   14-AUG-2000; 2000US-0225757.
PR   14-AUG-2000; 2000US-0225758.
PR   14-AUG-2000; 2000US-0225759.
PR   18-AUG-2000; 2000US-0226279.
PR   22-AUG-2000; 2000US-0226681.
PR   22-AUG-2000; 2000US-0226868.
PR   22-AUG-2000; 2000US-0227182.
PR   23-AUG-2000; 2000US-0227009.
PR   30-AUG-2000; 2000US-0228924.
PR   01-SEP-2000; 2000US-0229287.
PR   01-SEP-2000; 2000US-0229343.
PR   01-SEP-2000; 2000US-0229344.
PR   01-SEP-2000; 2000US-0229345.
PR   05-SEP-2000; 2000US-0229509.
PR   05-SEP-2000; 2000US-0229513.
PR   06-SEP-2000; 2000US-0230437.
PR   06-SEP-2000; 2000US-0230438.
PR   08-SEP-2000; 2000US-0231242.
PR   08-SEP-2000; 2000US-0231243.
PR   08-SEP-2000; 2000US-0231244.
PR   08-SEP-2000; 2000US-0231413.
PR   08-SEP-2000; 2000US-0231414.
PR   08-SEP-2000; 2000US-0232080.
PR   08-SEP-2000; 2000US-0232081.
PR   12-SEP-2000; 2000US-0231968.
PR   14-SEP-2000; 2000US-0232397.
PR   14-SEP-2000; 2000US-0232398.
PR   14-SEP-2000; 2000US-0232399.
PR   14-SEP-2000; 2000US-0232400.
PR   14-SEP-2000; 2000US-0232401.
PR   14-SEP-2000; 2000US-0233063.
PR   14-SEP-2000; 2000US-0233064.
PR   14-SEP-2000; 2000US-0233065.
PR   21-SEP-2000; 2000US-0234223.
PR   21-SEP-2000; 2000US-0234274.
PR   25-SEP-2000; 2000US-0234997.
PR   25-SEP-2000; 2000US-0234998.
PR   26-SEP-2000; 2000US-0235484.
PR   27-SEP-2000; 2000US-0235834.
PR   27-SEP-2000; 2000US-0235836.
PR   29-SEP-2000; 2000US-0236327.
PR   29-SEP-2000; 2000US-0236367.
PR   29-SEP-2000; 2000US-0236368.
PR   29-SEP-2000; 2000US-0236369.
PR   29-SEP-2000; 2000US-0236370.
PR   02-OCT-2000; 2000US-0236802.
PR   02-OCT-2000; 2000US-0237037.
PR   02-OCT-2000; 2000US-0237038.
PR   02-OCT-2000; 2000US-0237039.
PR   02-OCT-2000; 2000US-0237040.
PR   13-OCT-2000; 2000US-0239935.
PR   13-OCT-2000; 2000US-0239937.
PR   20-OCT-2000; 2000US-0240960.
PR   20-OCT-2000; 2000US-0241221.
PR   20-OCT-2000; 2000US-0241785.
PR   20-OCT-2000; 2000US-0241786.
PR   20-OCT-2000; 2000US-0241787.
PR   20-OCT-2000; 2000US-0241808.
PR   20-OCT-2000; 2000US-0241809.
PR   20-OCT-2000; 2000US-0241826.
PR   01-NOV-2000; 2000US-0244617.
PR   08-NOV-2000; 2000US-0246474.
PR   08-NOV-2000; 2000US-0246475.
PR   08-NOV-2000; 2000US-0246476.
PR   08-NOV-2000; 2000US-0246477.
PR   08-NOV-2000; 2000US-0246478.
PR   08-NOV-2000; 2000US-0246523.
PR   08-NOV-2000; 2000US-0246524.
PR   08-NOV-2000; 2000US-0246525.
PR   08-NOV-2000; 2000US-0246526.
PR   08-NOV-2000; 2000US-0246527.
PR   08-NOV-2000; 2000US-0246528.
PR   08-NOV-2000; 2000US-0246532.
PR   08-NOV-2000; 2000US-0246609.
PR   08-NOV-2000; 2000US-0246610.
PR   08-NOV-2000; 2000US-0246611.
PR   08-NOV-2000; 2000US-0246613.
```

```
PR   17-NOV-2000; 2000US-0249207.
PR   17-NOV-2000; 2000US-0249208.
PR   17-NOV-2000; 2000US-0249209.
PR   17-NOV-2000; 2000US-0249210.
PR   17-NOV-2000; 2000US-0249211.
PR   17-NOV-2000; 2000US-0249212.
PR   17-NOV-2000; 2000US-0249213.
PR   17-NOV-2000; 2000US-0249214.
PR   17-NOV-2000; 2000US-0249215.
PR   17-NOV-2000; 2000US-0249216.
PR   17-NOV-2000; 2000US-0249217.
PR   17-NOV-2000; 2000US-0249218.
PR   17-NOV-2000; 2000US-0249244.
PR   17-NOV-2000; 2000US-0249245.
PR   17-NOV-2000; 2000US-0249264.
PR   17-NOV-2000; 2000US-0249265.
PR   17-NOV-2000; 2000US-0249297.
PR   17-NOV-2000; 2000US-0249299.
PR   17-NOV-2000; 2000US-0249300.
PR   01-DEC-2000; 2000US-0250160.
PR   01-DEC-2000; 2000US-0250391.
PR   05-DEC-2000; 2000US-0251030.
PR   05-DEC-2000; 2000US-0251988.
PR   05-DEC-2000; 2000US-0256719.
PR   06-DEC-2000; 2000US-0251479.
PR   08-DEC-2000; 2000US-0251856.
PR   08-DEC-2000; 2000US-0251868.
PR   08-DEC-2000; 2000US-0251869.
PR   08-DEC-2000; 2000US-0251989.
PR   08-DEC-2000; 2000US-0251990.
PR   11-DEC-2000; 2000US-0254097.
PR   05-JAN-2001; 2001US-0259678.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Barash SC,  Ruben SM;
XX
DR   WPI; 2001-483426/52.
DR   N-PSDB; AAK63995.
XX
PT   Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
PT   useful for preventing, diagnosing and/or treating cancers and
PT   metastasis -
XX
PS   Claim 11; SEQ ID NO 18807; 3071pp + Sequence Listing; English.
XX
CC   AAK54951 to AAK64702 encode the human immune/haematopoietic antigen (I)
CC   amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic
CC   activity, and can be used in gene therapy and vaccine production. (I)
CC   proteins and polynucleotides may be used in the prevention, diagnosis and
CC   treatment of diseases associated with inappropriate (I) expression. For
CC   example, they may be used to treat disorders associated with decreased
CC   expression by rectifying mutations or deletions in a patient's genome
CC   that affect the activity of (I) by expressing inactive proteins or to
CC   supplement the patients own production of (I). Additionally, (I)
CC   polynucleotides may be used to produce the secreted (I), by inserting
CC   the nucleic acids into a host cell and culturing the cell to express the
CC   protein. (I) proteins and polynucleotides may be used to prevent,
CC   diagnose and treat immune/haematopoietic-related diseases, especially
CC   cancers and cancer metastases of haematopoietic-derived cells. AAK64703
CC   to AAK87694 represent human immune/haematopoietic antigen genomic
CC   sequences from the present invention. AAK54942 to AAK54950 and AAM82169
CC   represent sequences used in the exemplification of the present invention.
XX
SQ   Sequence   61 AA;

  Query Match             17.8%;  Score 74.5;  DB 22;  Length 61;
  Best Local Similarity   30.4%;  Pred. No. 0.21;
  Matches   17;  Conservative   10;  Mismatches    8;  Indels   21;  Gaps    1;

Qy          3 LSTHLFIYLFIYF--------------------LSYSLGDRARLCLRKTKQQQKE 37
              :: :|| : | :|                    |  ||||| ||||:| |:::|:
Db          4 ITKYLFCFGFFFFFEARESLELCGAEVTVSEIMPLHSSLGDRVRLCLKKKKKKKKK 59


RESULT 12
AAO07806
ID   AAO07806 standard; Protein; 99 AA.
XX
AC   AAO07806;
XX
DT   06-NOV-2001  (first entry)
XX
DE   Human polypeptide SEQ ID NO 21698.
XX
KW   Human; cytokine; cell proliferation; cell differentiation; gene therapy;
KW   vaccine; peptide therapy; stem cell growth factor; haematopoiesis;
KW   tissue growth factor; immunomodulatory; cancer; leukaemia;
KW   nervous system disorders; arthritis; inflammation.
XX
OS   Homo sapiens.
XX
PN   WO200164835-A2.
XX
PD   07-SEP-2001.
XX
PF   26-FEB-2001; 2001WO-US04927.
XX
PR   28-FEB-2000; 2000US-0515126.
PR   18-MAY-2000; 2000US-0577409.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Tang YT,  Liu C,  Drmanac RT;
XX
DR   WPI; 2001-514838/56.
DR   N-PSDB; AAI87737.
XX
PT   Isolated nucleic acids and polypeptides, useful for preventing
PT   diagnosing and treating e.g. leukaemia, inflammation and immune
PT   disorders -
XX
PS   Claim 20; SEQ ID NO 21698; 1399pp + Sequence Listing; English.
XX
CC   The invention relates to human polynucleotides (AAI79941-AAI93841) and
CC   the encoded proteins (AAO00010-AAO13910) that exhibit activity elating to
CC   cytokine, cell proliferation or cell differentiation or which may induce
CC   production of other cytokines in other cell populations. The
CC   polynucleotides and polypeptides are useful in gene therapy, vaccines or
CC   peptide therapy. The polypeptides have various cytokine-like activities,
CC   e.g. stem cell growth factor activity, haematopoiesis regulating
CC   activity, tissue growth factor activity, immunomodulatory activity and
CC   activin/inhibin activity and may be useful in the diagnosis and/or
CC   treatment of cancer, leukaemia, nervous system disorders, arthritis and
CC   inflammation.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   99 AA;

  Query Match             17.8%;  Score 74.5;  DB 22;  Length 99;
  Best Local Similarity   29.3%;  Pred. No. 0.35;
  Matches   17;  Conservative   14;  Mismatches   16;  Indels   11;  Gaps    2;

Qy         27 CLRKTKQQQKEQQILRQSEVLFRSETLRKTGKKGRRWGGQGG-----RGGTADTGGMF 79
              |::| |:::|:::  :      : :  :|  || : ||| ||     :||    || |
Db         39 CIKKKKKKKKKKKKKK------KKKKKKKKKKKKKLWGGGGGKNFFKKGGKKKLGGGF 90


RESULT 13
ABG29845
ID   ABG29845 standard; Protein; 924 AA.
XX
AC   ABG29845;
XX
```

```
DT   18-FEB-2002  (first entry)
XX
DE   Novel human diagnostic protein #29836.
XX
KW   Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW   food supplement; medical imaging; diagnostic; genetic disorder.
XX
OS   Homo sapiens.
XX
PN   WO200175067-A2.
XX
PD   11-OCT-2001.
XX
PF   30-MAR-2001; 2001WO-US08631.
XX
PR   31-MAR-2000; 2000US-0540217.
PR   23-AUG-2000; 2000US-0649167.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Drmanac RT,  Liu C,  Tang YT;
XX
DR   WPI; 2001-639362/73.
DR   N-PSDB; AAS94032.
XX
PT   New isolated polynucleotide and encoded polypeptides, useful in
PT   diagnostics, forensics, gene mapping, identification of mutations
PT   responsible for genetic disorders or other traits and to assess
PT   biodiversity -
XX
PS   Claim 20; SEQ ID No 60204; 103pp; English.
XX
CC   The invention relates to isolated polynucleotide (I) and
CC   polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC   polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC   and gene mapping, and in recombinant production of (II). The
CC   polynucleotides are also used in diagnostics as expressed sequence tags
CC   for identifying expressed genes. (I) is useful in gene therapy techniques
CC   to restore normal activity of (II) or to treat disease states involving
CC   (II). (II) is useful for generating antibodies against it, detecting or
CC   quantitating a polypeptide in tissue, as molecular weight markers and as
CC   a food supplement. (II) and its binding partners are useful in medical
CC   imaging of sites expressing (II). (I) and (II) are useful for treating
CC   disorders involving aberrant protein expression or biological activity.
CC   The polypeptide and polynucleotide sequences have applications in
CC   diagnostics, forensics, gene mapping, identification of mutations
CC   responsible for genetic disorders or other traits to assess biodiversity
CC   and to produce other types of data and products dependent on DNA and
CC   amino acid sequences. ABG00010-ABG30377 represent novel human
CC   diagnostic amino acid sequences of the invention.
CC   Note: The sequence data for this patent did not appear in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   924 AA;

  Query Match             17.6%;  Score 73.5;  DB 22;  Length 924;
  Best Local Similarity   33.7%;  Pred. No. 5.3;
  Matches   29;  Conservative   12;  Mismatches   28;  Indels   17;  Gaps    6;

Qy          9 IYLFIYFLSYSL--GDR----ARLCLRKTKQQQKEQQ--ILRQ---SEVLFRSETL---- 53
              : || |  |::|   |:    |:   | :: ||  |   |||    |:|  | : :
Db        802 VILFHYGESWNLLRADQRLIFAKSWPRASRYQQGHQDLFILRSDLPSQVFIRDKLMERRN 861

Qy         54 RKTGK--KGRRWGGQGGRGGTADTGG 77
              |:||:  | | ||  |  |   | ||
Db        862 RRTGRTEKARIWGSDGQNGQDLDWGG 887


RESULT 14
AAM86657
ID   AAM86657 standard; Protein; 59 AA.
XX
AC   AAM86657;
XX
DT   07-NOV-2001  (first entry)
XX
DE   Human immune/haematopoietic antigen SEQ ID NO:14250.
XX
KW   Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW   cytostatic; gene therapy; vaccine; metastasis.
XX
OS   Homo sapiens.
XX
PN   WO200157182-A2.
XX
PD   09-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US01354.
XX
PR   31-JAN-2000; 2000US-0179065.
PR   04-FEB-2000; 2000US-0180628.
PR   24-FEB-2000; 2000US-0184664.
PR   02-MAR-2000; 2000US-0186350.
PR   16-MAR-2000; 2000US-0189874.
PR   17-MAR-2000; 2000US-0190076.
PR   18-APR-2000; 2000US-0198123.
PR   19-MAY-2000; 2000US-0205515.
PR   07-JUN-2000; 2000US-0209467.
PR   28-JUN-2000; 2000US-0214886.
PR   30-JUN-2000; 2000US-0215135.
PR   07-JUL-2000; 2000US-0216647.
PR   07-JUL-2000; 2000US-0216880.
PR   11-JUL-2000; 2000US-0217487.
PR   11-JUL-2000; 2000US-0217496.
PR   14-JUL-2000; 2000US-0218290.
PR   26-JUL-2000; 2000US-0220963.
PR   26-JUL-2000; 2000US-0220964.
PR   14-AUG-2000; 2000US-0224518.
PR   14-AUG-2000; 2000US-0224519.
PR   14-AUG-2000; 2000US-0225213.
PR   14-AUG-2000; 2000US-0225214.
PR   14-AUG-2000; 2000US-0225266.
PR   14-AUG-2000; 2000US-0225267.
PR   14-AUG-2000; 2000US-0225268.
PR   14-AUG-2000; 2000US-0225270.
PR   14-AUG-2000; 2000US-0225447.
PR   14-AUG-2000; 2000US-0225757.
PR   14-AUG-2000; 2000US-0225758.
PR   14-AUG-2000; 2000US-0225759.
PR   18-AUG-2000; 2000US-0226279.
PR   22-AUG-2000; 2000US-0226681.
PR   22-AUG-2000; 2000US-0226868.
PR   22-AUG-2000; 2000US-0227182.
PR   23-AUG-2000; 2000US-0227009.
PR   30-AUG-2000; 2000US-0228924.
PR   01-SEP-2000; 2000US-0229287.
PR   01-SEP-2000; 2000US-0229343.
PR   01-SEP-2000; 2000US-0229344.
PR   01-SEP-2000; 2000US-0229345.
PR   05-SEP-2000; 2000US-0229509.
PR   05-SEP-2000; 2000US-0229513.
PR   06-SEP-2000; 2000US-0230437.
PR   06-SEP-2000; 2000US-0230438.
PR   08-SEP-2000; 2000US-0231242.
PR   08-SEP-2000; 2000US-0231243.
PR   08-SEP-2000; 2000US-0231244.
PR   08-SEP-2000; 2000US-0231413.
PR   08-SEP-2000; 2000US-0231414.
PR   08-SEP-2000; 2000US-0232080.
PR   08-SEP-2000; 2000US-0232081.
PR   12-SEP-2000; 2000US-0231968.
PR   14-SEP-2000; 2000US-0232397.
PR   14-SEP-2000; 2000US-0232398.
PR   14-SEP-2000; 2000US-0232399.
PR   14-SEP-2000; 2000US-0232400.
```

PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-483426/52.
DR N-PSDB; AAK59438.
XX
PT Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
PT useful for preventing, diagnosing and/or treating cancers and
PT metastasis -
XX
PS Claim 11; SEQ ID NO 14250; 3071pp + Sequence Listing; English.
XX
CC AAK54951 to AAK64702 encode the human immune/haematopoietic antigen (I)
CC amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic
CC activity, and can be used in gene therapy and vaccine production. (I)
CC proteins and polynucleotides may be used in the prevention, diagnosis and
CC treatment of diseases associated with inappropriate (I) expression. For
CC example, they may be used to treat disorders associated with decreased
CC expression by rectifying mutations or deletions in a patient's genome
CC that affect the activity of (I) by expressing inactive proteins or to
CC supplement the patients own production of (I). Additionally, (I)
CC polynucleotides may be used to produce the secreted (I), by inserting
CC the nucleic acids into a host cell and culturing the cell to express the
CC protein. (I) proteins and polynucleotides may be used to prevent,
CC diagnose and treat immune/haematopoietic-related diseases, especially
CC cancers and cancer metastases of haematopoietic-derived cells. AAK64703
CC to AAK87694 represent human immune/haematopoietic antigen genomic
CC sequences from the present invention. AAK54942 to AAK54950 and AAM82169
CC represent sequences used in the exemplification of the present invention.
XX
SQ Sequence 59 AA;

Query Match 17.5%; Score 73; DB 22; Length 59;
Best Local Similarity 45.7%; Pred. No. 0.3;
Matches 16; Conservative 9; Mismatches 10; Indels 0; Gaps 0;

```
Qy         13 IYFLSYSLGDRARLCLRKTKQQQKEQQILRQSEVL 47
              |  |  |||:||||||:| |:::|: :  |::  |
Db          3 ITLLRSSLGNRARLCLQKKKKKKKKGKEKRKARAL 37
```

RESULT 15
AAG84911
ID AAG84911 standard; Protein; 482 AA.
XX
AC AAG84911;
XX
DT 11-SEP-2001 (first entry)
XX
DE Shrimp white spot Bacilliform virus (WSBV) protein 2.
XX
KW Shrimp white spot Bacilliform virus; WSBV; diagnosis; viral infection;
KW antiviral agent; gene expression; antisense construct;
KW transgenic viral resistant shrimp.
XX
OS White spot syndrome virus.
XX
PN WO200138351-A2.
XX
PD 31-MAY-2001.
XX
PF 08-NOV-2000; 2000WO-US28888.
XX
PR 24-NOV-1999; 99CN-0124717.

XX
PA (PENY-) PE CORP NY.
PA (THIR-) THIRD INST OCEANOGRAPHY STATE OCEANI C A.
PA (SINO-) SINOGENOMAX CO LTD.
XX
PI Xu X, Yang F, He J, Pham L, He M, Ye Y, Shen Y, Kodira C;
XX
DR WPI; 2001-355877/37.
DR N-PSDB; AAH62691.
XX
PT Primary nucleotide sequence of the shrimp white spot Bacilliform virus
PT (WSBV), useful for producing viral polypeptides that can be used to
PT screen for agents that are useful for treating WSBV infection -
XX
PS Claim 1; Figure 3; 626pp; English.
XX
CC The invention provides the primary nucleotide sequence of the WSBV genome
CC (AAH62689), predicted transcript sequences (AAH62689-AAH62839) and
CC encoded proteins (AAG84910-AAG85051) and oligonucleotide sequences
CC (AAH62840-63160) suitable for use as primers or probes. The nucleic acid
CC molecules and proteins of the invention are useful for diagnosis and
CC monitoring viral infection, in screens for antiviral agents and for
CC monitoring viral gene expression or activity during a treatment regimen.
CC The nucleic acid molecules are also useful as antisense constructs to
CC control viral gene expression in infected cells and tissues and to create
CC transgenic viral resistant shrimp.
XX
SQ Sequence 482 AA;

Query Match 17.5%; Score 73; DB 22; Length 482;
Best Local Similarity 27.0%; Pred. No. 3;
Matches 20; Conservative 19; Mismatches 35; Indels 0; Gaps 0;

```
Qy          3 LSTHLFIYLFIYFLSYSLGDRARLCLRKTKQQQKEQQILRQSEVLFRSETLRKTGKKGRR 62
              ::| | :: |: |:| :: | |:    :  ::::.::  | ||     :    |   |
Db          6 IATSLVLFFFLLFVSITILDGAKTIDSQPFRKRRKRKRYRTSESGDGIDGGTGTTNGGGG 65

Qy         63 WGGQGGRGGTADTG 76
                ||:|| |||   |
Db         66 GGGEGGGGGTNGNG 79
```

Search completed: May 29, 2003, 15:18:12
Job time : 72 secs